We conducted a retrospective study with the aim of identifying risk factors and clinical characteristics associated with HBV reactivation and clinical flare after allogeneic stem cell transplantation (aSCT). We 
therefore constitute a reliable serological marker of a previous infection. [1] [2] [3] Clinical and biochemical remission, along with clearance of HBV-encoded antigens from the blood after an acute infectious episode, does not indicate complete HBV eradication. In patients who enter the immune stage of the HBV life cycle, minute viral quantities persist in the blood and peripheral blood mononuclear cells (PBMC) indefinitely. [4] [5] [6] [7] The HBV genome remains present in an episomal form with ongoing low-level transcription and replication in the liver tissue of HBcAb-positive healthy individuals. 8, 9 Conceivably, the HBcAb response may thus also reflect sustained restimulation of the host immune system by traces of nucleocapsid produced during continuous viral assembly. 8 In healthy immune individuals, a circulating reservoir of multispecific HBV-specific CD8 + cells is able to clonally expand and respond quickly to alterations in the HBV replication rate through cytolytic or non-cytolytic pathways of clearance. [10] [11] [12] [13] Vigorous anti-HBV T cell responses are detectable in vitro several years after clinical recovery from acute hepatitis B. 14 Rehermann et al 5 suggested that the T cell effector arm, as opposed to its B cell counterpart, is crucial in controlling the low HBV replication rate in HBcAb-positive persons and raised the issue of potential viral reactivation during immune suppression and/or dysfunction.
Hepatitis B reactivation with clinical flare has been sporadically reported in patients receiving chemotherapy for leukemia/lymphoma, graft-rejection prophylaxis for solid organ transplants, [15] [16] [17] [18] autologous and allogeneic stem cell transplantation (aSCT). [19] [20] [21] [22] [23] Due to the paucity of reported cases, predisposing events and clinical characteristics of HBV reactivation with clinical flare after aSCT are not well defined. The few cases reported have resulted in death due to liver failure or the persistence of a chronic carrier state. [19] [20] [21] [22] [23] The high endemicity of HBV in Saudi Arabia 24 provided us with a unique opportunity to assess this problem. Here, we provide evidence that patients with cGVHD treated with long-term immunosuppressive therapy are at significant risk of HBV reactivation with clinical flare, specifically at the time of drug tapering or withdrawal. The pattern of reactivation with clinical flare seems stereotyped and predictable. Of interest, treatment with lamivudine early in the course of the event seems to confer a favorable prognosis with clearance of HBV DNA in the blood and normalization of liver enzymes. Based on this observation, we suggest that in this high risk category of patients, serial monitoring of HBV DNA post transplant could lead to timely institution of pre-emptive anti-viral therapy and, possibly, suppression of clinical manifestations related to HBV reactivation following immunosuppressive therapy tapering or withdrawal.
Methods and patients
We reviewed the KFSH&RC International Bone Marrow Transplant Registry database from January 1998 to June 2000. One hundred and thirty-one patients were transplanted during this period. Of these, 128 (98%) had complete serological screening for HBV before the transplant. Fifty-four (42%) were positive for HBcAb. None of the donors and recipients were prospectively screened for HBV DNA before or after transplant. After transplant, HBV serology, HBV DNA testing, and liver biopsy were performed at the physician's discretion at the time of unexplained elevation of liver enzymes.
Eleven patients who died of early treatment-related mortality prior to day 100 could not be evaluated for longterm follow-up and were thus excluded from the study. One donor/recipient pair was excluded because the donor tested positive for HBsAg. Forty-two patients were evaluable for reactivation and follow-up. At the time of transplant, all donor/recipient pairs were negative for hepatitis B surface antigen while 10 donors (24%) tested positive for HBcAb. Four of six recipients were positive for HBsAb. The sources of hematopoietic stem cells included HLA matched sibling marrow in 39 patients, single antigen mismatched marrow in one, and HLA matched sibling mobilized peripheral blood stem cells in two. Clinical characteristics are summarized in Table 1 . Acute and chronic GVHD were diagnosed and graded according to Seattle guidelines. 25, 26 Patients with chronic GVHD not responding to an initial trial of steroids were switched to a long-term alternate day therapy regimen comprising steroids and cyclosporin A. 27 Hepatitis B virus reactivation with clinical flare was defined as seroconversion to HBsAg and HBeAg positivity, and/or detection of HBV DNA in the serum by polymerase chain reaction (PCR) concomitant with biochemical hepatitis. Hepatitis B virus markers (HBsAg, HBsAb, HBcAb, HBeAg, Anti-HBe) were screened for all recipients and donors using microparticle enzyme immunoassay (AxSYMSystem; Abbott Laboratories, Abbott Park, IL, USA). A positive result for HBsAg was repeated, and if positive again, this was confirmed using neutralization procedures (HBsAg Confirmatory Assay; Abbott Laboratories). Hepatitis B virus DNA detection was performed by PCR amplification using two sets of nested primers from the HPBADW2 gene (genebank) . One set of primers span positions 196-687, the other 1514-1955. DNA quantification was done using branched DNA assay for HBV (Quantiplex; Chiron, Emeryville, CA, USA).
Statistics
The relative risk (RR) estimates of HBV reactivation with 95% confidence intervals and P values were computed using SAS 8.0 package (SAS Institute, Inc, 1989). A correction of 0.5% was used in every cell of tables that contained a zero. The P values correspond to the two-sided Fisher's exact test.
Results
Six of 42 patients (14%) reactivated with clinical flare. We identified three distinct groups based on GVHD status at the time of the event ( The clinical characteristics of patients who reactivated with clinical flare are summarized in Table 3 . Median time from transplant to the event was 18 months (range 5.5-23 months). Median duration of corticosteroid therapy was 10 months (range 3.6-15 months). All patients had been off corticosteroid therapy prior to the event. Median duration of CsA or FK506 therapy from diagnosis of cGVHD to HBV reactivation with clinical flare was 11 months. The event occurred during CsA or FK506 therapy tapering in two patients, and shortly after complete withdrawal in four, at 20, 25, 25 and 40 days, respectively. The median peak elevation of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin were 679 U/l (range 217-3000 U/l), 1089 U/l (range 167-2250 U/l), and 268 mmol/l (25-358 mmol/l), respectively. At the time of clinical flare, all patients, except patient 2 who died of multiorgan failure at day +197 post transplant (33 days after reactivation), were treated with the purine nucleoside analog reverse transcriptase inhibitor lamivudine. Clearance of HBsAg, HBV DNA, and normalization of liver enzymes all occurred within a median time of 3 weeks (range 2-10 weeks) in the five patients evaluable for follow-up. Two weeks after inadvertently stopping lamivudine, patient 4 experienced an exacerbation of clinical flare confirmed by liver biopsy and was successfully re-treated with lamivudine.
At the time of HBV reactivation and clinical flare, two patients (patient 2 and 3, Table 3 ) presented with clinical evidence of concomitant cGVHD manifested by xerostomia, xerophthalmia, and oral lichen planus. Both had been off CsA therapy for 20 and 25 days, respectively, before the associated events. Reinstitution of immunosuppressive therapy, in addition to lamivudine, resulted in prompt resolution of clinical and biochemical signs of both events. Patient 2 reactivated early post transplant with no evidence of cGVHD (Table 3) . Unlike other patients who reactivated in this series, this patient's pre-transplant period was characterized by a severe immune deficiency state, associated with a protracted history of refractory lymphoblastic lymphoma requiring multiple cycles of chemotherapy and corticosteroids. With a median follow-up of 16 months after the event (range 10.3-24), HBV DNA and HBsAg are still negative in all five evaluable patients. Anti-viral therapy was discontinued after two consecutive HBV DNA negative results, 1 month apart. None of the patients became chronic carriers.
Discussion
In contrast to cytopathic viruses of the herpes family, 28, 29 reactivation of latent HBV infection with clinical flare after aSCT is relatively uncommon. Recent published guidelines and recommendations from the Centers for Disease Control, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation for the prevention of viral infections among hematopoietic stem cell transplant recipients do not allude to HBV reactivation. 30 The concept of latency with ongoing low-level viral replication in patients serologically immune after a primary HBV infection is quite new despite previous reports of HBV reactivation associated with chemotherapy and organ transplants. [15] [16] [17] [18] [19] [20] [21] [22] [23] We are now aware that minute quantities of transcriptionally active HBV genome probably remain for decades following complete clinical and serological recovery from acute hepatitis. [4] [5] [6] [7] 31 Michalak et al 32 recently demonstrated in the woodchuck model that the sites of occult lifelong maintenance of replicating HBV were the liver and lymphoid system. To our knowledge, this is the largest reported series describing HBV reactivation with clinical flare after aSCT in patients positive for HBcAb before transplant. Although reinoculation of HBV from blood products cannot be excluded, this is unlikely as our blood bank uses the American Association of Blood Banks' guidelines to ensure blood products safety from blood-borne pathogens (Auszyme; Abbot). Also, while the incubation period for hepatitis B is between 35 and 167 days, 33, 34 the median time to clinical flare up from the last blood product transfusion in our series was 18 months (range 4.5-19 months). Finally, 5/6 stem cell donors had not been exposed to HBV (HBcAb negative) before transplant and could not have transmitted the infection. We found that the risk of HBV reactivation with clinical flare was significant in patients with cGVHD. Five of 15 with cGVHD showed reactivation with clinical flare, in comparison to only 1/27 patients without cGVHD (RR: 9.0, 95% CI: 1.2-70.1 P Ͻ 0.02). Of note, reactivation with clinical flare occurred only in 13 of 15 patients with cGVHD requiring long-term alternate day therapy to control their disease. The pattern of clinical flare was predictable and stereotyped, with a late onset (median of 18 months post transplant), association with immunosuppressive therapy tapering or withdrawal, and rapid normalization of biochemical abnormalities (median of 3 weeks) with lamivudine therapy. A typical clinical course is illustrated in Figure 1 . All patients had been off corticosteroids before the event.
The association of cGVHD and HBV reactivation with clinical flare upon immunosuppressive therapy tapering and/or withdrawal has rarely been reported after aSCT. 22 This association is best explained by the fact that cGVHD is the most important predictive factor for poor thymic function post transplant. 35 This immune deficiency state constitutes a favorable terrain for unhindered HBV replication, without biochemical hepatitis due to the non-cytopathic nature of HBV. 36 Corticosteroids, which are an integral part of most cGVHD treatment regimens, can also synergize in promoting viral replication through direct HBV genomic transcriptional regulation. 37, 38 Direct CTLmediated lysis of infected cells through Fas-or perforinmediated mechanisms, rather than the virus itself, remains the principal although not the sole event determining the intensity of liver damage. 36 Consequently, successful treatment of cGVHD concomitant with immunosuppressive therapy withdrawal can then pave the way for resumption of T cell effector function and liver damage of variable intensity. Although the parenchymal damage was severe in some patients as judged by enzyme elevations (Table 3) preventing hepatocellular damage in HBV chronic carriers by decreasing HBV replication by 3 to 4 log copies in most patients, as early as 2 weeks after its administration. 39 Successful treatment of reactivated hepatitis B infection with lamivudine has recently been reported by others. [40] [41] [42] Of interest, two patients presented with clinical evidence of cGVHD in association with HBV reactivation and flare, manifested by typical lesions of oral lichen planus and sicca syndrome. The peak levels of serum aminotransferases were higher than generally observed in isolated cases of cGHVD. Because there was clear evidence of GVHD in other organs, we did not proceed to a liver biopsy. However, in cases of isolated clinical flare, a liver biopsy would be most helpful. Indeed, Strasser et al 43 recently reported a syndrome of cGVHD of the liver presenting as acute hepatitis, highlighting the difficulty in distinguishing between these two processes. This distinction has significant clinical implications, as implementation of immunosuppressive therapy following an erroneous diagnosis of cGVHD is likely to alleviate the clinical manifestations of both processes and mask an underlying HBV reactivation.
In summary, HBcAb-positive recipients with cGVHD are at significant risk of HBV reactivation with clinical flare. This event seems predictable and early administration of lamivudine upon diagnosis seems to confer a good prognosis. Awareness of the association between HBV reactivation and cGVHD is especially relevant when one considers that cGVHD occurs in the majority of patients receiving HLA non-identical-related transplants, matched unrelated transplants, and HLA matched mobilized peripheral blood allogeneic stem cell transplants. 44, 45 As suggested by Strasser and McDonald, 46 these patients should be monitored for HBV DNA from 2 weeks post transplant. Early initiation of pre-emptive antiviral therapy upon obtaining positive results may abrogate HBV replication during the window of post-transplant defective thymopoiesis and limit CTL-induced hepatocellular damage at the critical time of immune recovery and immunosuppressive therapy withdrawal. Persico et al 47 recently reported the successful use of lamivudine given as prophylaxis. In this setting, re-establishment of tolerance to a small viral load via T cell effector function recovery obviates the need for further treatment. It must be stressed that a significant proportion of patients with negative HBsAg and high-titer antiHBc have HBV DNA in the sera before transplant. 48 Although there is at present no strong evidence to suggest that these patients are likely to be at higher risk of reactivation after transplant, prophylactic anti-viral therapy in this specific group of patients could prove beneficial.
